Business Presentation - Oct 2025
Overview
Earthwise Nutraceuticals is raising $5m to establish a 70,000 sq ft outsourced contract manufacturing organization (CMO) for wellness brands producing natural supplement products — tablets, capsules, powders, and liquids.
We specialize in plant-based, clean-label formulations aligned with rising consumer demand for natural health products.
Financial Highlights
Total Raise: $5M
$10M
Year 1 Revenue
Increasing to $31.6M in 2030
50%
Gross Margin
Strong unit economics
30%
EBITDA Margin
Healthy profitability
103.9%
IRR
Exceptional investor returns
44%+
ROE
Return on equity
7.0x
Strong DSCR
Debt service coverage ratio
The Problem
Supply Chain Instability
Offshore dependence creates unreliable delivery and quality control issues.
Limited Clean-Label Options
Lack of affordable U.S. manufacturing for natural, transparent formulations.
High Barriers to Entry
Major CMOs require high MOQs and long lead times, blocking emerging brands.
Trust Gap
Low confidence in ingredient quality and transparency from offshore suppliers.
Our Solution
GMP-Compliant Facility
Fully equipped U.S. manufacturing meeting highest quality standards.
Rapid Turnaround
1–2 weeks development, 4 weeks reorders — industry-leading speed.
Smaller MOQs
Brand flexibility with accessible minimum order quantities.
End-to-End Production
Complete service: sourcing, compounding, packaging, fulfillment.
Market Opportunity
$130.5B
2034 Market Size
U.S. Nutraceutical CMO market projected growth
12.3%
CAGR
Compound annual growth rate through 2034
$22.8B
SAM
Supplement CMO sub-sector serviceable market
  • Clean-label, cognitive health, and natural trends expanding faster than traditional VMS categories.
  • E-commerce and private-label explosion fueling small-batch production demand.
Business Model
Manufacturing Contracts
Core recurring B2B CMO revenue stream
Formulation Consulting
Expert guidance for custom product development
White-Label Development
Complete product solutions for brands
Future DTC Brand
Direct consumer product line expansion
Competitive Advantages
1
Local Manufacturing
U.S.-based operations ensure supply chain reliability, consistent pricing, and faster turnaround.
2
Comprehensive CMO Services
Full production spectrum — powders, tablets, capsules, softgels, liquids — with packaging for premium and value-tier products.
3
Custom Formulation Expertise
In-house experts co-create new formulations for niche markets, driving higher margins and customer loyalty.
4
Smaller MOQs
Capture emerging brands and fast-growth niches often ignored by large CMOs.
5
Quality Sourcing at Affordable Prices
Trusted suppliers across U.S., Canada, Mexico, New Zealand, and Australia enable transparency and premium quality without inflating cost.
Traction & Pipeline
9
Immediate Clients
Waiting to place orders, representing ~$18M revenue
40+
Sales Relationships
Existing long-standing relationships worth $50M+ in potential revenue
$1.5M
Monthly Throughput
Expected immediate ramp-up capacity per month
Contingent Customers
(Values based on existing actual order levels of these specific customers. Soft commitments received, contingent on GMP-compliant factory setup and AR terms.)
Operations & Tampa Bay Facility
70,000 sq ft GMP-compliant manufacturing center
Climate-Controlled Production Zones
  • Pharmacy
  • Blending
  • Encapsulation
  • Liquids
  • Packaging
Capacity to handle 2x volume with upgrades
Sachets
Tablets
Capsules
Liquids
Powders
Combination Packs
Team & Advisors
Ted Jackson, CEO
37 years nutraceutical/pharma management experience. Developed 1,500+ formulations. (link)
Osmel Martinez, COO
30 years pharma manufacturing operations. GMP compliance specialist.
Dave Amelin, Sales Director
30 years fitness & nutraceutical sales. Large existing client network. (link)
Stephen Lieberman, Advisor
Former FDA official. Regulatory attorney & quality expert.
Investor Opportunity
Early Entry
$5M raise into an undervalued, asset-backed CMO with proven demand.
Fast Growth
Recurring B2B revenues with 50%+ gross margins and scalable operations.
Exit Potential
Strategic acquisition or equity buyout within 5–7 years.
Target IRR
75–100% based on conservative growth model and market dynamics.
Uses of Capital
Total Capital Raise:
$5,000,000
Strategic allocation across equipment, facility preparation, and operational runway to ensure successful launch and scale.
Use of Capital Timeline
1
Setup (mo 0)
Equip Purchase - $1,18m
*(Equip det in next slide)
Prof & Closing - $30k
TOTAL - $1,21m
2
Start Ops (mo 1-3)
Opex Runway - $380k
(Fixed exp, Variable exp, Salaries, etc)
Facility Buildout - $880k
TOTAL - $1,26m
3
Start Manuf. (mo 4)
Opex Runway - $230k
Purchase Inventory - $241k
TOTAL - $471k
4
Start Sales (mo 5-7)
Opex Runway - $208
AR Cushion - $991k
Purchase Inventory - $241k
TOTAL - $1,44m
Contingency Fund - $614k
TOTAL
$5m
Equipment & FFE Details
Profit & Loss - 5 Yrs to 2030
Balance Sheet - 5 Yrs to 2030
For a copy of the detailed business plan, click below:
Click here
📞 Contact
Ted Jackson
ewn.finance@gmail.com
📞 Contact
Henry Land
hl@trajectory.financial
🟢 Prepared By
Henry Land